Roche's companion Dx for lung cancer drug wins FDA nod

05/15/2013 | Medscape (free registration) · Fox Business

The FDA has approved Roche's cobas EGFR Mutation Test as a companion diagnostic for Tarceva, or erlotinib, a nonsmall-cell lung cancer drug developed by Roche's Genentech unit. The test, designed to determine which patients will benefit from Tarceva, is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor mutations found in around 10% of nonsmall-cell lung cancer.

View Full Article in:

Medscape (free registration) · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY